Lincus | Home

Engineered gamma-peptide nucleic acids to inhibit miR-122-mediated diabetes and diabetic vasculopathy

Sponsor: DHHS/NIH/National Heart, Lung, and Blood Institute/University of Iowa

Authors: Raman Bahal

2025-07-01 - 2028-06-30

Beta-cells miR-204 is remotely governed by gut-microbiota and promotes diabetes

Sponsor: American Diabetes Association/University of Iowa

Authors: Raman Bahal

2019-01-01 - 2020-12-31

Site Specific Genome Editing of Hematopoietic Stem Cells for Sickle Cell Disease Gene Therapy

Sponsor: Connecticut Innovations

Authors: Raman Bahal

Funding: $200,000

2017-08-23 - 2019-06-15

Nanodelivery therapeutic systems for substance use disorder

Sponsor: DHHS/NIH/National Institute on Drug Abuse

Authors: Raman Bahal

Funding: $241,500

2020-09-30 - 2022-09-29

Next generation targeting multiple oncomiRs for cancer therapy

Sponsor: DHHS/NIH/National Institutes of Health

Authors: Raman Bahal

2019-09-01 - 2024-08-31

Next generation gamma Peptide Nucleic Acids (?PNAs) for the treatment of ischemic stroke

Sponsor: DHHS/NIH/National Institute of Neurological Disorders and Stroke/University of Connecticut Health Center

Authors: Raman Bahal

Funding: $177,100

2020-05-15 - 2023-04-30

Developing chemically modified RNA inhibitors to treat liver fibrosis

Sponsor: DHHS/NIH/National Institutes of Health/Beth Israel Deaconess Medical Center

Authors: Raman Bahal

2024-04-01 - 2029-03-31

Next-generation microRNA inhibitors for urological malignancy

Sponsor: DHHS/NIH/National Institutes of Health/Eastern Virginia Medical School

Authors: Raman Bahal

2025-12-01 - 2030-11-30

Genetic correction of homozygous familial hypercholesterolemia (FH) using triplex-forming peptide nucleic acid

Sponsor: DHHS/NIH/National Institutes of Health/Yale University

Authors: Raman Bahal

2019-01-01 - 2020-12-31

Kidney-targeted chemically modified glycoconjugates-based RNA therapeutics for ADPKD

Sponsor: DHHS/NIH/National Institutes of Health/Yale University

Authors: Raman Bahal

2025-12-01 - 2030-11-30

Triplex induced gene editing for Gaucher diseases

Sponsor: DHHS/NIH/National Institutes of Health/Yale University

Authors: Raman Bahal

2019-09-01 - 2024-08-31

Next generation targeting of tumor microenvironment for cancer therapy

Sponsor: St. Baldrick's Foundation

Authors: Raman Bahal

Funding: $100,000

2019-07-01 - 2020-06-30

Next generation targeted delivery of antimiR probes for cancer therapy

Sponsor: DHHS/NIH/National Cancer Institute

Authors: Raman Bahal

2019-04-01 - 2021-03-31

Developing a Novel System for Pediatric Cancer Therapy: Tumor-Targeted Inhibition of Oncogenic MicroRNAs

Sponsor: Pediatric Cancer Research Foundation

Authors: Raman Bahal

2019-01-01 - 2021-12-31

Developing next generation synthetic nucleic acid analogous for sickle cell disease

Sponsor: DHHS/NIH/National Heart, Lung, and Blood Institute

Authors: Raman Bahal

Funding: $2,000,300

2019-12-15 - 2025-11-30

Macrophage Specific Regulatory Role of Mir-33 in Pulmonary Fibrosis

Sponsor: DOD/Department of Defense/Yale University

Authors: Raman Bahal

2023-03-01 - 2027-02-28

Targeted delivery of antimiR gamma PNAs for lymphoma therapy

Sponsor: American Foundation for Pharmaceutical Education

Authors: Raman Bahal

2018-06-01 - 2019-08-31

Advancing Stroke Treatment with yPNA-Based miR-141-3p Inhibitors

Sponsor: American Heart Association/University of Connecticut Health Center

Authors: Raman Bahal

2025-07-01 - 2028-06-30

Developing a Sequence-Specific VEGFA Genomic DNA Inhibitor for Cancer Therapy

Sponsor: DHHS/NIH/National Institutes of Health

Authors: Raman Bahal

2025-12-01 - 2027-11-30

Non-nuclease based gene editing for Hutchison-Guilford Progeria

Sponsor: DHHS/NIH/National Institute on Aging/Yale University

Authors: Raman Bahal

Funding: $201,313

2021-01-01 - 2022-12-31

Are you Raman Bahal?

How to update your information.